We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 06, 2021

Efficacy of Pazopanib ± Gemcitabine in Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma

JAMA Oncology

 

Additional Info

JAMA Oncology
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial
JAMA Oncol 2020 Dec 23;[EPub Ahead of Print], H-J Schmoll, LH Lindner, P Reichardt, et al

Further Reading